Its rarity in clinical practice is likely due to the simultaneous engagement of immune escape mechanisms, such as the recruitment of regulatory CD4+ (Treg) and myeloid-derived suppressor cells counterbalancing the anti-tumor CD8+ T cell-mediated effects, and the tumor release of hypoxia-inducible factors with pro-survival activity Ji et al. The gene discussed is CD4; the disease is neoplasm.